Cardinal Health (CAH) 10-Q 7 Nov 17 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	cah
Entity Registrant Name	CARDINAL HEALTH INC
Entity Central Index Key	721,371
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		320,063,302

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Revenue	$ 32,641	$ 32,039
Cost of products sold	30,969	30,449
Gross margin	1,672	1,590
Operating expenses:
Distribution, selling, general and administrative expenses	1,062	920
Restructuring and employee severance	132	9
Amortization and other acquisition-related costs	183	122
Impairments and (gain)/loss on disposal of assets, net	1	3
Litigation (recoveries)/charges, net	32	1
Operating earnings	262	535
Other (income)/expense, net	2	(3)
Interest expense, net	81	44
Loss on extinguishment of debt	1	0
Earnings before income taxes	178	494
Provision for income taxes	61	184
Net earnings	117	310
Net earnings attributable to noncontrolling interests	(2)	(1)
Net earnings attributable to Cardinal Health, Inc.	$ 115	$ 309
Earnings per common share attributable to Cardinal Health, Inc.:
Basic (in shares)	$ 0.36	$ 0.97
Diluted (in shares)	$ 0.36	$ 0.96
Weighted-average number of common shares outstanding:
Basic (in shares)	316	320
Diluted (in shares)	318	322
Cash dividends declared per common share	$ 0.4624	$ 0.4489

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net earnings	$ 117	$ 310
Other comprehensive income:
Foreign currency translation adjustments and other	40	(1)
Net unrealized gain/(loss) on derivative instruments, net of tax	(1)	1
Total other comprehensive income, net of tax	39	0
Total comprehensive income	156	310
Less: comprehensive income attributable to noncontrolling interests	(2)	(1)
Total comprehensive income attributable to Cardinal Health, Inc.	$ 154	$ 309

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2017	Jun. 30, 2017
Current assets:
Cash and equivalents	$ 1,181	$ 6,879
Trade receivables, net	8,382	8,048
Inventories, net	12,121	11,301
Prepaid expenses and other	2,041	2,117
Total current assets	23,725	28,345
Property and equipment, net	2,651	1,879
Goodwill and other intangibles, net	14,926	9,207
Other assets	638	681
Total assets	41,940	40,112
Current liabilities:
Accounts payable	19,202	17,906
Current portion of long-term obligations and other short-term borrowings	935	1,327
Other accrued liabilities	2,270	1,988
Total current liabilities	22,407	21,221
Long-term obligations, less current portion	9,068	9,068
Deferred income taxes and other liabilities	3,758	2,877
Redeemable noncontrolling interests	12	118
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none	0	0
Common shares, without par value:
Authorized—755 million shares, Issued—327 million shares and 327 million shares at September 30, 2017 and June 30, 2017, respectively	2,674	2,697
Retained earnings	4,943	4,967
Common shares in treasury, at cost: 12 million shares and 11 million shares at September 30, 2017 and June 30, 2017, respectively	(853)	(731)
Accumulated other comprehensive loss	(86)	(125)
Total Cardinal Health, Inc. shareholders' equity	6,678	6,808
Noncontrolling interests	17	20
Total shareholders’ equity	6,695	6,828
Total liabilities, redeemable noncontrolling interests and shareholders’ equity	$ 41,940	$ 40,112

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	Sep. 30, 2017	Jun. 30, 2016
Statement of Financial Position [Abstract]
Preferred shares, authorized	500,000	500,000
Preferred shares, issued	0	0
Common shares, authorized	755,000,000	755,000,000
Common shares, issued	364,000,000	364,000,000
Common shares in treasury	44,000,000	42,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net earnings	$ 117	$ 310
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	229	173
Loss on extinguishment of debt	1	0
Impairments and loss on sale of other investments	6	0
Impairments and (gain)/loss on disposal of assets, net	1	3
Share-based compensation	(17)	(23)
Provision for bad debts	25	7
Change in operating assets and liabilities, net of effects from acquisitions:
Increase in trade receivables	(359)	(306)
Increase in inventories	(381)	(298)
Increase in accounts payable	1,296	279
Other accrued liabilities and operating items, net	229	(87)
Net cash provided by operating activities	1,181	104
Cash flows from investing activities:
Acquisition of subsidiaries, net of cash acquired	(6,139)	(9)
Additions to property and equipment	(67)	(100)
Purchase of available-for-sale securities and other investments	(3)	(52)
Proceeds from sale of available-for-sale securities and other investments	64	34
Proceeds from Sale of Property, Plant, and Equipment	1	0
Proceeds from maturities of available-for-sale securities	0	17
Net cash used in investing activities	(6,144)	(110)
Cash flows from financing activities:
Payment of contingent consideration obligation	(15)	0
Net change in short-term borrowings	(6)	25
Purchase of noncontrolling interests	(3)	(10)
Reduction of long-term obligations	(402)	(1)
Proceeds from interest rate swap terminations	0	14
Net tax withholdings from share-based compensation	(18)	(9)
Excess tax benefits from share-based compensation	0	30
Dividends on common shares	(150)	(149)
Purchase of treasury shares	(150)	(250)
Net cash used in financing activities	(744)	(350)
Effect of exchange rates changes on cash and equivalents	9	1
Net decrease in cash and equivalents	(5,698)	(355)
Cash and equivalents at beginning of period	6,879	2,356
Cash and equivalents at end of period	$ 1,181	$ 2,001

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2018 and 2017 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2018 and June 30, 2017, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2018 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2018 . These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017 (the " 2017 Form 10-K"). Recent Financial Accounting Standards In August 2017, the Financial Accounting Standards Board (the "FASB") issued accounting guidance which is intended to improve and simplify accounting rules around hedge accounting. The guidance will be effective for us in the first quarter of fiscal 2020 and early adoption is permitted. We are currently evaluating the impact of this standard on our condensed consolidated financial statements. In March 2016, the FASB issued amended accounting guidance that changed the accounting for certain aspects of share-based compensation to employees. The guidance requires all income tax effects of share-based awards to be recognized in the statement of earnings as awards vest or are settled. Additionally, the guidance increases the amount employers can withhold in shares to cover employee income taxes without requiring liability classification and allows a policy election for accounting for forfeitures. The primary impact of adoption resulted in the recognition of excess tax benefits in the statement of earnings on a prospective basis, rather than as a component of equity. The impact on the presentation in the condensed consolidated statement of cash flows is also prospective. We adopted this guidance in the first quarter of fiscal 2018. The impact of adoption on the provision for income taxes on our condensed consolidated statement of earnings was immaterial. The inclusion of excess tax benefits and deficiencies as a component of our income tax expense will increase volatility within our provision for income taxes as the amount of excess tax benefits or deficiencies from share- based compensation awards depends on our stock price at the date the awards vest. In May 2014, the FASB issued amended accounting guidance related to revenue recognition. This guidance is based on the principle that revenue is recognized in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The FASB also subsequently issued several amendments to the standard, including clarification on principal versus agent considerations, performance obligations and licensing, and certain scope improvements and practical expedients. We continue to make progress on our evaluation of the amended revenue recognition guidance, including identification of revenue streams and customer contract reviews. Our revenue is primarily distribution revenue, which we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Although we are continuing to assess the impact of the amended guidance, we generally anticipate that the timing of recognition of distribution revenue will be substantially unchanged under the amended guidance.

Acquisitions

Acquisitions	3 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Acquisitions	2. Acquisitions Patient Recovery Business On July 29, 2017, we acquired the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses (the "Patient Recovery Business") from Medtronic plc for $6.1 billion in cash. The Patient Recovery Business manufactures 23 categories of medical products sold into multiple healthcare channels, and includes numerous industry-leading brands, such as Curity, Kendall, Dover, Argyle and Kangaroo. The acquisition further expands the Medical segment's portfolio of self-manufactured products. We closed the Patient Recovery Business acquisition in 28 principal countries on July 29, 2017 , and acquired control of, as described in GAAP, and the rights to, the net economic benefit from the entire Patient Recovery Business in the remaining countries at the closing. We are in the process of transitioning legal ownership in the remaining non-principal countries, which we expect to complete by the end of calendar 2018. The results for the entire Patient Recovery Business in all countries are included in the condensed consolidated financial statements beginning July 29, 2017. We funded the acquisition through $4.5 billion in new long-term debt, the use of existing cash and borrowings under our existing credit arrangements. Transaction and integration costs associated with the acquisition of the Patient Recovery business were $37 million during the three months ended September 30, 2017 , and are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings. Fair Value of Assets Acquired and Liabilities Assumed The allocation of the purchase price for the acquisition of the Patient Recovery Business is not yet finalized and is subject to adjustment as we complete the valuation analysis for this acquisition. The purchase price is subject to adjustment based on working capital requirements as set forth in the acquisition agreement. The valuation of identifiable intangible assets utilizes significant unobservable inputs and thus represents a Level 3 nonrecurring fair value measurement. The estimated fair value of the identifiable intangible assets was determined using income-based approaches, which includes market participant expectations of the cash flows that an asset could generate over its economic life, discounted back to present value using an appropriate rate of return. The weighted- average discount rate used to arrive at the present value of the identifiable intangible assets was 8.2 percent , and considers the inherent risk of each intangible asset relative to the internal rate of return and weighted-average cost of capital. The following table summarizes the estimated fair value of the assets acquired and liabilities assumed as of the acquisition date for the Patient Recovery Business: (in millions) Patient Recovery Business Identifiable intangible assets: Customer relationships (1) $ 1,712 Trade names (2) 186 Developed technology and other (3) 732 Total identifiable intangible assets acquired 2,630 Cash and equivalents 24 Inventories 434 Prepaid expenses and other 106 Property and equipment, net 807 Other accrued liabilities (153 ) Deferred income taxes and other liabilities (873 ) Total identifiable net assets acquired/(liabilities) assumed 2,975 Goodwill 3,103 Total net assets acquired $ 6,078 (1) The range of useful lives for customer relationships is 10 to 18 years. (2) The useful life of trade names is 15 years. (3) The useful life of developed technology is 15 years.

Restructuring and Employee Seve

Restructuring and Employee Severance	3 Months Ended
	Sep. 30, 2017
Restructuring Charges [Abstract]
Restructuring and Employee Severance	3. Restructuring and Employee Severance The following table summarizes restructuring and employee severance costs: Three months ended September 30, (in millions) 2017 2016 Employee-related costs (1) $ 4 $ 7 Facility exit and other costs (2) 128 2 Total restructuring and employee severance $ 132 $ 9 (1) Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. (2) Facility exit and other costs primarily consist of product distribution and lease contract termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services. In September 2017, we entered into an agreement to transition the distribution of our Medical segment's surgeon gloves in certain international markets from a third-party distribution arrangement to a direct distribution model. The expected costs with this restructuring include $125 million , on a pre-tax basis, in contract termination costs. These costs are reflected in facility exit and other costs in the condensed consolidated statements of earnings during the three months ended September 30, 2017. The contract termination costs are expected to be paid before the end of fiscal 2018. The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2017 $ 41 $ — $ 41 Additions 2 127 129 Payments and other adjustments (9 ) — (9 ) Balance at September 30, 2017 $ 34 $ 127 $ 161

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	4. Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical Total Balance at June 30, 2017 $ 2,939 $ 4,282 $ 7,221 Goodwill acquired, net of purchase price adjustments 1 3,156 3,157 Foreign currency translation adjustments and other 11 30 41 Balance at September 30, 2017 $ 2,951 $ 7,468 $ 10,419 The increase in the Medical segment goodwill is primarily due to the Patient Recovery Business acquisition. Goodwill recognized in connection with the Patient Recovery Business acquisition primarily represents the expected benefits from certain synergies of integrating the business, the existing workforce of the acquired entity, and the expected growth from new customers. Other Intangible Assets The following tables summarize other intangible assets by class at: September 30, 2017 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 61 $ — $ 61 N/A Total indefinite-life intangibles 61 — 61 N/A Definite-life intangibles: Customer relationships 3,705 1,046 2,659 13 Trademarks, trade names, and patents 697 212 485 13 Developed technology and other 1,648 346 1,302 12 Total definite-life intangibles 6,050 1,604 4,446 13 Total other intangible assets $ 6,111 $ 1,604 $ 4,507 N/A June 30, 2017 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 61 $ — $ 61 Total indefinite-life intangibles 61 — 61 Definite-life intangibles: Customer relationships 1,966 967 999 Trademarks, trade names, and patents 509 195 314 Developed technology and other 916 304 612 Total definite-life intangibles 3,391 1,466 1,925 Total other intangible assets $ 3,452 $ 1,466 $ 1,986 The increase in definite-life intangibles is primarily due to the Patient Recovery Business acquisition. Total amortization of intangible assets was $135 million and $101 million for the three months ended September 30, 2017 and 2016 , respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2018 through 2022 is as follows: $444 million , $563 million , $531 million , $458 million , and $421 million .

Available-for-Sale Securities

Available-for-Sale Securities	3 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Available-for-Sale Securities	5. Available-for-Sale Securities We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. We held the following investments in marketable securities at fair value at: (in millions) September 30, 2017 June 30, 2017 Treasury bills $ — $ 25 International bonds — 3 Corporate bonds — 30 U.S. agency bonds — 3 Asset-backed securities — 3 International equity securities — 1 Total available-for-sale securities $ — $ 65 In July 2017, we liquidated our marketable securities. There were no unrealized gains or loss at September 30, 2017 , and gross unrealized gains and losses were immaterial at June 30, 2017 . During the three months ended September 30, 2017 and 2016, gross realized gains and losses were immaterial and we did not recognize any other-than-temporary impairments.

Long-Term Obligations and Other

Long-Term Obligations and Other Short-Term Borrowings	3 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	6. Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt At September 30, 2017 and June 30, 2017 , we had total long term obligations, including the current portion, of $10.0 billion and $10.4 billion , respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $19.2 billion . In June 2017, we issued additional debt with the aggregate principal amount of $5.2 billion to fund a portion of the acquisition of the Patient Recovery Business, to redeem the $400 million 1.7% Notes due 2018 and for general corporate purposes. In July 2017, we redeemed the $400 million 1.7% Notes due 2018. The notes issued in June 2017 were 1.948% Notes due 2019, 2.616% Notes due 2022, 3.079% Notes due 2024, 3.410% Notes due 2027, 4.368% Notes due 2047, and floating rate Notes due 2022. Other Financing Arrangements In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion revolving credit facility and a $1.0 billion committed receivables sales facility program. At September 30, 2017 , we had no amounts outstanding under the revolving credit facility or the committed receivables sales facility program. In November 2016, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through November 1, 2019. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes Fluctuations in our provision for income taxes as a percentage of pretax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. During the three months ended September 30, 2017 and 2016 , the effective tax rate was 34.2 percent and 37.3 percent , respectively. The decrease in the effective tax rate was due to the impact of discrete items. At September 30, 2017 and June 30, 2017 , we had $410 million and $417 million of unrecognized tax benefits, respectively. The September 30, 2017 and June 30, 2017 balances include $266 million and $268 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. At September 30, 2017 and June 30, 2017 , we had $97 million and $99 million , respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $35 million , exclusive of penalties and interest. We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $144 million and $142 million at September 30, 2017 and June 30, 2017 , respectively, and is included in other assets in the condensed consolidated balance sheets.

Commitments, Contingent Liabili

Commitments, Contingent Liabilities and Litigation	3 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingent Liabilities and Litigation	8. Commitments, Contingent Liabilities and Litigation Commitments Generic Sourcing Venture with CVS Health Corporation ("CVS Health") In July 2014 , we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years . Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of both companies. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term. Legal Proceedings We become involved from time to time in disputes, litigation, and regulatory matters. We may be named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government . From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions. From time to time, we may determine that products we manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, action by regulators and product liability claims and lawsuits, including class actions. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. We recognize income from the favorable outcome of litigation when we receive the associated cash or assets. We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings. Opioid Lawsuits As of October 30, 2017, 98 counties and municipalities, one state attorney general and one tribal entity have filed lawsuits against pharmaceutical wholesale distributors (including us) relating to the distribution of prescription opioid pain medications. Many of the lawsuits also include pharmaceutical manufacturers and retail chains. We are also a defendant in a purported class action lawsuit brought on behalf of unions and other health and welfare funds that paid for certain opioid prescriptions on behalf of their members. These lawsuits, which have been filed in various federal, state and other courts, allege violations of controlled substance laws and various other statutes as well as common law claims, including negligence, public nuisance and unjust enrichment, and seek equitable relief and monetary damages. We are vigorously defending ourselves in these lawsuits. Since these lawsuits are in early stages, we are unable to predict their outcome or estimate a range of reasonably possible losses. In September 2017, we, along with other distributors, received a request for information related to an investigation being conducted by a group of approximately 40 U.S. state attorneys general. We also have received civil investigative demands, subpoenas or requests for information from several individual state attorneys general offices. These investigations are focused on the distribution of opioid medication. We are currently evaluating and responding to their requests. Product Liability Lawsuits As of October 30, 2017, we are named as a defendant in 90 product liability lawsuits filed in Alameda County Superior Court in California involving claims by approximately 1,030 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another 15 similar lawsuits involving claims by approximately 25 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We are vigorously defending ourselves in these lawsuits. At September 30, 2017, we had a total of $ 129 million , net of expected insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits. While we have recorded accruals based on our assessment of these matters, because these lawsuits are in early stages, we are unable to estimate a range of reasonably possible losses in excess of this accrued amount.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Fair Value Measurements The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: September 30, 2017 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,162 $ — $ — $ 1,162 Available-for-sale securities (2) — — — — Other investments (3) 116 — — 116 Liabilities: Forward contracts (1) — (21 ) — (21 ) Contingent consideration (4) — — (23 ) (23 ) June 30, 2017 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 739 $ — $ — $ 739 Available-for-sale securities (2) — 65 — 65 Other investments (3) 116 — — 116 Liabilities: Forward contracts (1) — (21 ) — (21 ) Contingent consideration (4) — — (32 ) (32 ) (1) The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets. (2) We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities. (3) The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (4) Contingent consideration represents the obligations incurred in connection with acquisitions. We do not deem the fair value of the contingent consideration obligations under any single acquisition to be significant. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or of achieving certain milestones. The fair value measurement is based on significant inputs unobservable in the market and thus represents a Level 3 measurement. Changes in current expectations of progress could change the probability of achieving the targets within the measurement periods and result in an increase or decrease in the fair value of the contingent consideration obligation. The following table presents those liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3): (in millions) Contingent Consideration Obligation Balance at June 30, 2017 $ 32 Additions from acquisitions 5 Changes in fair value of contingent consideration (1) — Payment of contingent consideration (15 ) Balance at September 30, 2017 $ 23 The sum of the components may not equal the total due to rounding. (1) Amount is included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.

Financial Instruments

Financial Instruments	3 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	10. Financial Instruments We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to fair value through earnings at the end of each period. Our derivative and hedging programs are consistent with those described in the 2017 Form 10-K. The amount of ineffectiveness associated with these derivative instruments was immaterial for the three months ended September 30, 2017 and 2016 . Fair Value of Financial Instruments The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2017 and June 30, 2017 approximate fair value due to their short-term maturities. The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) September 30, 2017 June 30, 2017 Estimated fair value $ 10,333 $ 10,713 Carrying amount 10,003 10,395 The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	3 Months Ended
	Sep. 30, 2017
Temporary Equity [Abstract]
Redeemable Noncontrolling Interests	In connection with the acquisition of a 71 percent ownership interest in naviHealth during fiscal 2016, we recognized redeemable noncontrolling interest with a fair value of $119 million at the acquisition date. The noncontrolling interests are redeemable at the option of the third-party noncontrolling interests holders at any time after the two-year anniversary of the closing. During the three months ended September 30, 2017 , certain third-party noncontrolling interest holders notified us of their intent to exercise their put right on the noncontrolling interest representing 16 percent of naviHealth with a carrying value of $103 million and a redemption value of $ 109 million . Upon notification of the intent to exercise the put, the carrying value of the 16 percent of naviHealth became mandatorily redeemable and was reclassified to other accrued liabilities in the condensed consolidated balance sheet. The reconciliation of the changes in redeemable noncontrolling interests are as follows: (in millions) Redeemable Noncontrolling Interest Balance at June 30, 2017 $ 118 Net earnings attributable to redeemable noncontrolling interests 1 Net purchase of redeemable noncontrolling interests (103 ) Adjustment of redeemable noncontrolling interests to redemption value (5 ) Balance at September 30, 2017 $ 12 In October 2017, we settled the $103 million mandatorily redeemable liability with cash, which resulted in our ownership interest in naviHealth increasing to 98 percent .

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Shareholders' Equity	12. Shareholders' Equity During the three months ended September 30, 2017 , we repurchased 2.2 million common shares having an aggregate cost of $150 million . The average price paid per common share was $67.92 . We funded the repurchases with available cash and short-term borrowings. During the three months ended September 30, 2016 , we repurchased 3.1 million common shares having an aggregate cost of $250 million . The average price paid per common share was $81.37 . We funded the repurchases with available cash The common shares repurchased are held in treasury to be used for general corporate purposes. Accumulated Other Comprehensive Loss The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2017 $ (148 ) $ 23 $ (125 ) Other comprehensive income/(loss), before reclassifications 40 (1 ) 39 Amounts reclassified to earnings — — — Other comprehensive income/(loss), net of tax 40 (1 ) 39 Balance at September 30, 2017 $ (108 ) $ 22 $ (86 ) Activity related to realized gains and losses on available-for-sale securities, as described in Note 5 , was immaterial during the three months ended September 30, 2017 . There were no unrealized gains and losses on available-for-sale securities at September 30, 2017 .

Earnings Per Share Attributable

Earnings Per Share Attributable to Cardinal Health, Inc.	3 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share Attributable to Cardinal Health, Inc.	13. Earnings Per Share Attributable to Cardinal Health, Inc. The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.: Three Months Ended September 30, (in millions) 2017 2016 Weighted-average common shares–basic 316 320 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 2 2 Weighted-average common shares–diluted 318 322 The potentially dilutive employee stock options, restricted share units, and performance share units that were antidilutive for the three months ended September 30, 2017 and 2016 were 5 million and 3 million , respectively.

Segment Information

Segment Information	3 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Segment Information	14. Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. The following table presents revenue for each reportable segment and Corporate: Three Months Ended September 30, (in millions) 2017 2016 Pharmaceutical $ 28,920 $ 28,762 Medical 3,724 3,279 Total segment revenue 32,644 32,041 Corporate (1) (3 ) (2 ) Total revenue $ 32,641 $ 32,039 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance. The results attributable to noncontrolling interests are recorded within segment profit. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; other income, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes. In addition, certain investment spending, certain portions of enterprise-wide incentive compensation, and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. We encourage our segments and corporate functions to identify investment projects that will promote innovation and provide future returns. As approval decisions for such projects are dependent upon executive management, the expenses for such projects are often retained at Corporate. Investment spending within Corporate was $5 million and $1 million for the three months ended September 30, 2017 and 2016 , respectively. The following table presents segment profit by reportable segment and Corporate: Three Months Ended September 30, (in millions) 2017 2016 Pharmaceutical $ 467 $ 534 Medical 129 127 Total segment profit 596 661 Corporate (334 ) (126 ) Total operating earnings $ 262 $ 535 The following table presents total assets for each reportable segment and Corporate at: (in millions) September 30, June 30, Pharmaceutical $ 22,220 $ 21,848 Medical 18,055 10,688 Corporate 1,665 7,576 Total assets $ 41,940 $ 40,112

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	15. Share-Based Compensation We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. The following table provides total share-based compensation expense by type of award: Three Months Ended September 30, (in millions) 2017 2016 Restricted share unit expense $ 18 $ 17 Employee stock option expense 5 5 Performance share unit expense (6 ) 1 Total share-based compensation $ 17 $ 23 The total tax benefit related to share-based compensation was $6 million and $8 million for the three months ended September 30, 2017 and 2016 , respectively. As of July 1, 2017 , under ASU 2016-09, excess tax benefits, which are immaterial for the three months ended September 30, 2017 , are prospectively recognized within the provision for income taxes on our condensed consolidated statements of earnings and prospectively recognized as operating activity on our condensed consolidated statement of cash flows. Restricted Share Units Restricted share units granted under the Plans generally vest in equal annual installments over three years . Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2017 2 $ 76.72 Granted 1 66.44 Vested (1 ) 79.53 Canceled and forfeited — — Nonvested at September 30, 2017 2 $ 71.60 At September 30, 2017 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $117 million , which is expected to be recognized over a weighted-average period of two years . Stock Options Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date. The following table summarizes all stock option transactions under the Plans: (in millions, except per share amounts) Stock Options Weighted-Average Exercise Price per Common Share Outstanding at June 30, 2017 6 $ 63.44 Granted 2 66.44 Exercised — — Canceled and forfeited — — Outstanding at September 30, 2017 8 $ 64.30 Exercisable at September 30, 2017 5 $ 59.19 At September 30, 2017 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $35 million , which is expected to be recognized over a weighted-average period of two years . The following tables provide additional detail related to stock options: (in millions) September 30, 2017 June 30, 2017 Aggregate intrinsic value of outstanding options at period end $ 65 $ 109 Aggregate intrinsic value of exercisable options at period end 65 106 (in years) September 30, 2017 June 30, 2017 Weighted-average remaining contractual life of outstanding options 7 7 Weighted-average remaining contractual life of exercisable options 6 6 Performance Share Units Performance share units vest over a three -year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 200 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2017 0.6 $ 77.83 Granted 0.2 66.43 Vested (1) (0.2 ) 71.57 Canceled and forfeited — — Nonvested at September 30, 2017 0.6 $ 75.39 (1) Vested based on achievement of 133 percent of the target performance goal. At September 30, 2017 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $18 million , which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.

Basis of Presentation and Sum22

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2018 and 2017 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2018 and June 30, 2017, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2018 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2018 . These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2017 (the " 2017 Form 10-K").
Recent Financial Accounting Standards	Recent Financial Accounting Standards In August 2017, the Financial Accounting Standards Board (the "FASB") issued accounting guidance which is intended to improve and simplify accounting rules around hedge accounting. The guidance will be effective for us in the first quarter of fiscal 2020 and early adoption is permitted. We are currently evaluating the impact of this standard on our condensed consolidated financial statements. In March 2016, the FASB issued amended accounting guidance that changed the accounting for certain aspects of share-based compensation to employees. The guidance requires all income tax effects of share-based awards to be recognized in the statement of earnings as awards vest or are settled. Additionally, the guidance increases the amount employers can withhold in shares to cover employee income taxes without requiring liability classification and allows a policy election for accounting for forfeitures. The primary impact of adoption resulted in the recognition of excess tax benefits in the statement of earnings on a prospective basis, rather than as a component of equity. The impact on the presentation in the condensed consolidated statement of cash flows is also prospective. We adopted this guidance in the first quarter of fiscal 2018. The impact of adoption on the provision for income taxes on our condensed consolidated statement of earnings was immaterial. The inclusion of excess tax benefits and deficiencies as a component of our income tax expense will increase volatility within our provision for income taxes as the amount of excess tax benefits or deficiencies from share- based compensation awards depends on our stock price at the date the awards vest. In May 2014, the FASB issued amended accounting guidance related to revenue recognition. This guidance is based on the principle that revenue is recognized in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The FASB also subsequently issued several amendments to the standard, including clarification on principal versus agent considerations, performance obligations and licensing, and certain scope improvements and practical expedients. We continue to make progress on our evaluation of the amended revenue recognition guidance, including identification of revenue streams and customer contract reviews. Our revenue is primarily distribution revenue, which we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Although we are continuing to assess the impact of the amended guidance, we generally anticipate that the timing of recognition of distribution revenue will be substantially unchanged under the amended guidance.

Acquisitions Business Combinati

Acquisitions Business Combinations (Tables)	3 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the estimated fair value of the assets acquired and liabilities assumed as of the acquisition date for the Patient Recovery Business: (in millions) Patient Recovery Business Identifiable intangible assets: Customer relationships (1) $ 1,712 Trade names (2) 186 Developed technology and other (3) 732 Total identifiable intangible assets acquired 2,630 Cash and equivalents 24 Inventories 434 Prepaid expenses and other 106 Property and equipment, net 807 Other accrued liabilities (153 ) Deferred income taxes and other liabilities (873 ) Total identifiable net assets acquired/(liabilities) assumed 2,975 Goodwill 3,103 Total net assets acquired $ 6,078 (1) The range of useful lives for customer relationships is 10 to 18 years. (2) The useful life of trade names is 15 years. (3) The useful life of developed technology is 15 years.

Restructuring and Employee Se24

Restructuring and Employee Severance (Tables)	3 Months Ended
	Sep. 30, 2017
Restructuring Charges [Abstract]
Summary of Restructuring and Employee Severance	The following table summarizes restructuring and employee severance costs: Three months ended September 30, (in millions) 2017 2016 Employee-related costs (1) $ 4 $ 7 Facility exit and other costs (2) 128 2 Total restructuring and employee severance $ 132 $ 9 (1) Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. (2) Facility exit and other costs primarily consist of product distribution and lease contract termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance	The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2017 $ 41 $ — $ 41 Additions 2 127 129 Payments and other adjustments (9 ) — (9 ) Balance at September 30, 2017 $ 34 $ 127 $ 161

Goodwill and Other Intangible25

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill by Reportable Segment	The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical Total Balance at June 30, 2017 $ 2,939 $ 4,282 $ 7,221 Goodwill acquired, net of purchase price adjustments 1 3,156 3,157 Foreign currency translation adjustments and other 11 30 41 Balance at September 30, 2017 $ 2,951 $ 7,468 $ 10,419
Schedule of Finite-Lived Intangible Assets	The following tables summarize other intangible assets by class at: September 30, 2017 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 61 $ — $ 61 N/A Total indefinite-life intangibles 61 — 61 N/A Definite-life intangibles: Customer relationships 3,705 1,046 2,659 13 Trademarks, trade names, and patents 697 212 485 13 Developed technology and other 1,648 346 1,302 12 Total definite-life intangibles 6,050 1,604 4,446 13 Total other intangible assets $ 6,111 $ 1,604 $ 4,507 N/A June 30, 2017 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 61 $ — $ 61 Total indefinite-life intangibles 61 — 61 Definite-life intangibles: Customer relationships 1,966 967 999 Trademarks, trade names, and patents 509 195 314 Developed technology and other 916 304 612 Total definite-life intangibles 3,391 1,466 1,925 Total other intangible assets $ 3,452 $ 1,466 $ 1,986
Schedule of Indefinite-Lived Intangible Assets	The following tables summarize other intangible assets by class at: September 30, 2017 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 61 $ — $ 61 N/A Total indefinite-life intangibles 61 — 61 N/A Definite-life intangibles: Customer relationships 3,705 1,046 2,659 13 Trademarks, trade names, and patents 697 212 485 13 Developed technology and other 1,648 346 1,302 12 Total definite-life intangibles 6,050 1,604 4,446 13 Total other intangible assets $ 6,111 $ 1,604 $ 4,507 N/A June 30, 2017 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 61 $ — $ 61 Total indefinite-life intangibles 61 — 61 Definite-life intangibles: Customer relationships 1,966 967 999 Trademarks, trade names, and patents 509 195 314 Developed technology and other 916 304 612 Total definite-life intangibles 3,391 1,466 1,925 Total other intangible assets $ 3,452 $ 1,466 $ 1,986

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	3 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	We held the following investments in marketable securities at fair value at: (in millions) September 30, 2017 June 30, 2017 Treasury bills $ — $ 25 International bonds — 3 Corporate bonds — 30 U.S. agency bonds — 3 Asset-backed securities — 3 International equity securities — 1 Total available-for-sale securities $ — $ 65

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: September 30, 2017 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,162 $ — $ — $ 1,162 Available-for-sale securities (2) — — — — Other investments (3) 116 — — 116 Liabilities: Forward contracts (1) — (21 ) — (21 ) Contingent consideration (4) — — (23 ) (23 ) June 30, 2017 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 739 $ — $ — $ 739 Available-for-sale securities (2) — 65 — 65 Other investments (3) 116 — — 116 Liabilities: Forward contracts (1) — (21 ) — (21 ) Contingent consideration (4) — — (32 ) (32 ) (1) The fair value of interest rate swaps, foreign currency contracts and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets. (2) We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities. (3) The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (4) Contingent consideration represents the obligations incurred in connection with acquisitions. We do not deem the fair value of the contingent consideration obligations under any single acquisition to be significant. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or of achieving certain milestones. The fair value measurement is based on significant inputs unobservable in the market and thus represents a Level 3 measurement. Changes in current expectations of progress could change the probability of achieving the targets within the measurement periods and result in an increase or decrease in the fair value of the contingent consideration obligation.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table presents those liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3): (in millions) Contingent Consideration Obligation Balance at June 30, 2017 $ 32 Additions from acquisitions 5 Changes in fair value of contingent consideration (1) — Payment of contingent consideration (15 ) Balance at September 30, 2017 $ 23 The sum of the components may not equal the total due to rounding. (1) Amount is included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) September 30, 2017 June 30, 2017 Estimated fair value $ 10,333 $ 10,713 Carrying amount 10,003 10,395

Redeemable Noncontrolling Int29

Redeemable Noncontrolling Interests (Tables)	3 Months Ended
	Sep. 30, 2017
Temporary Equity [Abstract]
Reconciliation of the Changes in Redeemable Noncontrolling Interests	The reconciliation of the changes in redeemable noncontrolling interests are as follows: (in millions) Redeemable Noncontrolling Interest Balance at June 30, 2017 $ 118 Net earnings attributable to redeemable noncontrolling interests 1 Net purchase of redeemable noncontrolling interests (103 ) Adjustment of redeemable noncontrolling interests to redemption value (5 ) Balance at September 30, 2017 $ 12 In October 2017, we settled the $103 million mandatorily redeemable liability with cash, which resulted in our ownership interest in naviHealth increasing to 98 percent .

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total	Accumulated Other Comprehensive Loss The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2017 $ (148 ) $ 23 $ (125 ) Other comprehensive income/(loss), before reclassifications 40 (1 ) 39 Amounts reclassified to earnings — — — Other comprehensive income/(loss), net of tax 40 (1 ) 39 Balance at September 30, 2017 $ (108 ) $ 22 $ (86 )

Earnings Per Share Attributab31

Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)	3 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share	Three Months Ended September 30, (in millions) 2017 2016 Weighted-average common shares–basic 316 320 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 2 2 Weighted-average common shares–diluted 318 322

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Revenue by Reportable Segment	The following table presents revenue for each reportable segment and Corporate: Three Months Ended September 30, (in millions) 2017 2016 Pharmaceutical $ 28,920 $ 28,762 Medical 3,724 3,279 Total segment revenue 32,644 32,041 Corporate (1) (3 ) (2 ) Total revenue $ 32,641 $ 32,039 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment	Three Months Ended September 30, (in millions) 2017 2016 Pharmaceutical $ 467 $ 534 Medical 129 127 Total segment profit 596 661 Corporate (334 ) (126 ) Total operating earnings $ 262 $ 535
Assets by Reportable Segment	(in millions) September 30, June 30, Pharmaceutical $ 22,220 $ 21,848 Medical 18,055 10,688 Corporate 1,665 7,576 Total assets $ 41,940 $ 40,112

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Total Share-based Compensation Expense by Type of Award	The following table provides total share-based compensation expense by type of award: Three Months Ended September 30, (in millions) 2017 2016 Restricted share unit expense $ 18 $ 17 Employee stock option expense 5 5 Performance share unit expense (6 ) 1 Total share-based compensation $ 17 $ 23
Schedule of Stock Option Transactions Under the Plans	The following table summarizes all stock option transactions under the Plans: (in millions, except per share amounts) Stock Options Weighted-Average Exercise Price per Common Share Outstanding at June 30, 2017 6 $ 63.44 Granted 2 66.44 Exercised — — Canceled and forfeited — — Outstanding at September 30, 2017 8 $ 64.30 Exercisable at September 30, 2017 5 $ 59.19
Schedule of Additional Data Related to Stock Option Activity	The following tables provide additional detail related to stock options: (in millions) September 30, 2017 June 30, 2017 Aggregate intrinsic value of outstanding options at period end $ 65 $ 109 Aggregate intrinsic value of exercisable options at period end 65 106 (in years) September 30, 2017 June 30, 2017 Weighted-average remaining contractual life of outstanding options 7 7 Weighted-average remaining contractual life of exercisable options 6 6
Schedule of Transactions Related to Restricted Share Units Under the Plans	The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2017 2 $ 76.72 Granted 1 66.44 Vested (1 ) 79.53 Canceled and forfeited — — Nonvested at September 30, 2017 2 $ 71.60
Schedule of Transactions Related to Performance Share Units Under the Plans	The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2017 0.6 $ 77.83 Granted 0.2 66.43 Vested (1) (0.2 ) 71.57 Canceled and forfeited — — Nonvested at September 30, 2017 0.6 $ 75.39 (1) Vested based on achievement of 133 percent of the target performance goal.

Basis of Presentation and Sum34

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Facility Exit and Other Costs	$ 128	$ 2

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Millions	Jul. 29, 2017USD ($)categorycountry	Jun. 30, 2017USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Business Acquisition [Line Items]
Cash paid for acquisitions, net of cash acquired			$ 6,139	$ 9
Patient Recovery Business [Member]
Business Acquisition [Line Items]
Prepaid expenses and other			106
Cash paid for acquisitions, net of cash acquired	$ 6,100
Number of Product Categories Manufactured | category	23
Number of principal countries | country	28
Proceeds from Issuance of Debt		$ 4,500
Transaction and integration costs			$ 37
Level 3 | Patient Recovery Business [Member]
Business Acquisition [Line Items]
Fair Value Inputs, Discount Rate	8.20%

Acquisitions (Acquisition) (Det

Acquisitions (Acquisition) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Business Acquisition [Line Items]
Goodwill	$ 10,419	$ 7,221
Patient Recovery Business [Member]
Business Acquisition [Line Items]
Total identifiable intangible assets acquired	2,630
Cash and equivalents	24
Inventories	434
Prepaid expenses and other	106
Property and equipment, net	807
Other accrued liabilities	(153)
Deferred income taxes and other liabilities	(873)
Total identifiable net assets acquired/(liabilities) assumed	2,975
Goodwill	3,103
Total net assets acquired	6,078
Customer relationships | Patient Recovery Business [Member]
Business Acquisition [Line Items]
Identifiable intangible assets:	$ 1,712
Trade Names [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Trade Names [Member] | Patient Recovery Business [Member]
Business Acquisition [Line Items]
Identifiable intangible assets:	$ 186
Developed Technology Rights [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Developed Technology Rights [Member] | Patient Recovery Business [Member]
Business Acquisition [Line Items]
Identifiable intangible assets:	$ 732
Minimum | Customer relationships
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Maximum | Customer relationships
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	18 years

Restructuring and Employee Se37

Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Employee-related costs	$ 4	$ 7
Facility Exit and Other Costs	128	2
Total restructuring and employee severance	$ 132	$ 9

Restructuring and Employee Se38

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2017USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 41
Additions	129
Payments and other adjustments	(9)
Ending Balance	161
Employee- Related Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	41
Additions	2
Payments and other adjustments	(9)
Ending Balance	34
Facility Exit and Other Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Additions	127
Payments and other adjustments	0
Ending Balance	$ 127

Restructuring and Employee Se39

Restructuring and Employee Severance Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Facility Exit and Other Costs	$ 128	$ 2
Medline [Member]
Restructuring Cost and Reserve [Line Items]
Facility Exit and Other Costs	$ 125

Goodwill and Other Intangible40

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2017USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 7,221
Goodwill acquired, net of purchase price adjustments	3,157
Foreign currency translation adjustments and other	41
Ending balance	10,419
Pharmaceutical
Goodwill [Roll Forward]
Beginning balance	2,939
Goodwill acquired, net of purchase price adjustments	1
Foreign currency translation adjustments and other	11
Ending balance	2,951
Medical
Goodwill [Roll Forward]
Beginning balance	4,282
Goodwill acquired, net of purchase price adjustments	3,156
Foreign currency translation adjustments and other	30
Ending balance	$ 7,468

Goodwill and Other Intangible41

Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2016
Indefinite-lived Intangible Assets [Line Items]
Net Intangible	$ 61	$ 61
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	6,050	3,391
Accumulated Amortization	1,604	1,466
Net Intangible	$ 4,446	1,925
Weighted- Average Remaining Amortization Period (Years)	13 years
Gross Intangible, Total other intangible assets	$ 6,111	3,452
Net Intangible, Total other intangible assets	4,507	1,986
IPR&D, trademarks and other
Indefinite-lived Intangible Assets [Line Items]
Net Intangible	61
IPR&D, trademarks and other
Indefinite-lived Intangible Assets [Line Items]
Net Intangible		61
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	3,705	1,966
Accumulated Amortization	1,046	967
Net Intangible	$ 2,659	999
Weighted- Average Remaining Amortization Period (Years)	13 years
Trademarks, trade names, and patents
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	$ 697	509
Accumulated Amortization	212	195
Net Intangible	$ 485	314
Weighted- Average Remaining Amortization Period (Years)	13 years
Developed technology and other
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	$ 1,648	916
Accumulated Amortization	346	304
Net Intangible	$ 1,302	$ 612
Weighted- Average Remaining Amortization Period (Years)	12 years

Goodwill and Other Intangible42

Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 135	$ 101
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	444
Finite-Lived Intangible Assets, Amortization Expense, Year Two	563
Finite-Lived Intangible Assets, Amortization Expense, Year Three	531
Finite-Lived Intangible Assets, Amortization Expense, Year Four	458
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 421

Available-for-Sale Securities43

Available-for-Sale Securities (Schedule of Available-for-Sale Securities) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Jun. 30, 2017
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities		$ 65
Treasury bills
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities	$ 0	25
International bonds
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities	0	3
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities	0	30
U.S. agency bonds
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities	0	3
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities	0	3
International equity securities
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities	0	1
Recurring
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities	0	65
Level 2 | Recurring
Schedule of Available-for-sale Securities [Line Items]
Total available-for-sale securities	$ 0	$ 65

Long-Term Obligations and Oth44

Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jun. 30, 2017	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt and Capital Lease Obligations	$ 10,395	$ 10,003
Accounts payable	$ 17,906	19,202
1.7% Notes due fiscal 2018 [Member]
Debt Instrument [Line Items]
Notes Payable		400
Debt Instrument, Interest Rate, Stated Percentage	1.70%
1.948% Notes due 2019 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.948%
2.616% Notes due fiscal 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.616%
3.079% Notes due fiscal 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.079%
3.41% Notes due fiscal 2027 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.41%
4.368% Notes due fiscal 2047 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.368%
Patient Recovery Business [Member]
Debt Instrument [Line Items]
Proceeds from Notes Payable	$ 5,200
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		2,000
Revolving Credit Facility [Member] | Committed Receivables Sales Facility Program [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding		0
Short Term Credit Facilities Member | Committed Receivables Sales Facility Program [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,000

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Income Taxes
Effective Income Tax Rate Reconciliation, Percent	34.20%	37.30%
Unrecognized tax benefits	$ 410	$ 417
Unrecognized tax benefits that would impact effective tax rate	266	268
Unrecognized tax benefits, interest and penalties accrued	97	99
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority	144	$ 142
Minimum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months	0
Maximum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months	$ 35
Federal | Minimum
Income Taxes
Tax years open for examination	2,008
State and Local | Minimum
Income Taxes
Tax years open for examination	2,008
Foreign | Minimum
Income Taxes
Tax years open for examination	2,008

Commitments, Contingent Liabi46

Commitments, Contingent Liabilities and Litigation (Details) $ in Millions	Oct. 31, 2017organizationplaintifflawsuit	Jul. 31, 2014	Sep. 30, 2017USD ($)
Loss Contingencies [Line Items]
Loss Contingency, Request for Information			40
Loss Contingency Accrual, Net of Insurance Recoveries | $			$ 129
Subsequent Event
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff	1,030
Product Liability Lawsuits [Member] | Subsequent Event
Loss Contingencies [Line Items]
Number of lawsuits filed	15
Number of plaintiffs | organization	25
CVS Health
Loss Contingencies [Line Items]
Initial term of pharmaceutical sourcing venture		10 years
Maximum quarterly payment | $			$ 45.6
Opioid Lawsuits [Member] | Subsequent Event
Loss Contingencies [Line Items]
Number of lawsuits filed	98
Product Liability Lawsuits [Member] | Subsequent Event
Loss Contingencies [Line Items]
Number of lawsuits filed	90

Fair Value Measurements (Fair V

Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Jun. 30, 2017
Assets:
Total available-for-sale securities		$ 65
Recurring
Assets:
Cash equivalents	$ 1,162	739
Total available-for-sale securities	0	65
Other investments	116	116
Derivative Assets (Liabilities), at Fair Value, Net	(21)	(21)
Liabilities:
Contingent Consideration	(23)	(32)
Recurring | Level 1
Assets:
Cash equivalents	1,162	739
Total available-for-sale securities	0	0
Other investments	116	116
Derivative Assets (Liabilities), at Fair Value, Net	0	0
Liabilities:
Contingent Consideration	0	0
Recurring | Level 2
Assets:
Cash equivalents	0	0
Total available-for-sale securities	0	65
Other investments	0	0
Derivative Assets (Liabilities), at Fair Value, Net	(21)	(21)
Liabilities:
Contingent Consideration	0	0
Recurring | Level 3
Assets:
Cash equivalents	0	0
Total available-for-sale securities	0	0
Other investments	0	0
Derivative Assets (Liabilities), at Fair Value, Net	0	0
Liabilities:
Contingent Consideration	$ (23)	$ (32)

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - Recurring - Contingent Consideration Obligation $ in Millions	3 Months Ended
	Sep. 30, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 32
Additions from acquisitions	5
Changes in fair value of contingent consideration	0
Payment of contingent consideration	(15)
Balance at end of period	$ 23

Financial Instruments (Summary

Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Jun. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	$ 10,003	$ 10,395
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	$ 10,333	$ 10,713

Redeemable Noncontrolling Int50

Redeemable Noncontrolling Interests (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Oct. 31, 2017	Jun. 30, 2017	Aug. 26, 2015
Redeemable Noncontrolling Interest [Line Items]
Redeemable Noncontrolling Interest, Equity, Carrying Amount	$ 12		$ 118
naviHealth
Redeemable Noncontrolling Interest [Line Items]
Ownership interest (as a percent)	98.00%			71.00%
Redeemable Noncontrolling Interest, Equity, Fair Value				$ 119
Decrease from purchase of interest	16.00%
Adjustment of redeemable noncontrolling interests to redemption value	$ 103
Redeemable Noncontrolling Interest, Equity, Carrying Amount	12		$ 118
Redeemable Noncontrolling Interest, Equity, Redemption Value	$ 109
Subsequent Event | naviHealth
Redeemable Noncontrolling Interest [Line Items]
Redeemable Noncontrolling Interest, Equity, Carrying Amount		$ 103

Redeemable Noncontrolling Int51

Redeemable Noncontrolling Interests (Changes in Redeemable Noncontrolling Interests) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2017USD ($)
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance at June 30, 2017	$ 118
Balance at September 30, 2017	12
naviHealth
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance at June 30, 2017	118
Net earnings attributable to redeemable noncontrolling interests	1
Adjustment of redeemable noncontrolling interests to redemption value	103
Balance at September 30, 2017	12
Noncontrolling Interest, Change in Redemption Value	$ (5)

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - Treasury Shares - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Class of Stock [Line Items]
Treasury shares acquired (using cost method), shares	2.2	3.1
Payments for Repurchase of Common Stock	$ 150	$ 250
Treasury shares acquired, average price per share (in usd per share)	$ 67.92	$ 81.37

Shareholders' Equity (Changes i

Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	$ 6,828
Total other comprehensive income, net of tax	39	$ 0
Balance at end of period	6,695
Foreign Currency Translation Adjustments
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(148)
Other comprehensive income/(loss), before reclassifications	40
Amounts reclassified to earnings	0
Total other comprehensive income, net of tax	40
Balance at end of period	(108)
Unrealized Gain/(Loss) on Derivatives, net of tax
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	23
Other comprehensive income/(loss), before reclassifications	(1)
Amounts reclassified to earnings	0
Total other comprehensive income, net of tax	(1)
Balance at end of period	22
Accumulated Other Comprehensive Loss
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(125)
Other comprehensive income/(loss), before reclassifications	39
Amounts reclassified to earnings	0
Total other comprehensive income, net of tax	39
Balance at end of period	$ (86)

Earnings Per Share Attributab54

Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares shares in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Effect of dilutive securities:
Weighted-average common shares–basic (in shares)	316	320
Weighted Average Number Diluted Shares Outstanding Adjustment	2	2
Weighted-average common shares–diluted (in shares)	318	322

Earnings Per Share Attributab55

Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares shares in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)	5	3

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2017USD ($)segment	Sep. 30, 2016USD ($)segment
Segment Reporting [Abstract]
Number of operating segments	2
Number of reportable segments		2
Project Costs On Investment And Other Spending | $	$ 5	$ 1

Segment Information (Revenue by

Segment Information (Revenue by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Total revenue	$ 32,641	$ 32,039
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	32,644	32,041
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total revenue	28,920	28,762
Operating Segments | Medical
Segment Reporting Information [Line Items]
Total revenue	3,724	3,279
Corporate
Segment Reporting Information [Line Items]
Total revenue	$ (3)	$ (2)

Segment Information (Segment Pr

Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	$ 262	$ 535
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	596	661
Operating Segments | Pharmaceutical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	467	534
Operating Segments | Medical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	129	127
Corporate
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	$ (334)	$ (126)

Segment Information (Assets by

Segment Information (Assets by Reportable Segment) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Jun. 30, 2017
Segment Reporting Information [Line Items]
Total assets	$ 41,940	$ 40,112
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total assets	22,220	21,848
Operating Segments | Medical
Segment Reporting Information [Line Items]
Total assets	18,055	10,688
Corporate
Segment Reporting Information [Line Items]
Total assets	$ 1,665	$ 7,576

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit related to share-based compensation	$ 6	$ 8
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 35
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Exercisable period of plans (in years)	10 years
Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 117
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Performance Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 18
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Target performance goal (as a percent)	133.00%
Performance Share Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)	0.00%
Performance Share Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)	200.00%

Share-Based Compensation (Sched

Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 17	$ 23
Restricted Share Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	18	17
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	5	5
Performance Share Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ (6)	$ 1

Share-Based Compensation (Sch62

Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) shares in Millions	3 Months Ended
	Sep. 30, 2017$ / sharesshares
Stock Options
Outstanding at beginning of period (in shares) | shares	6
Granted (in shares) | shares	2
Exercised (in shares) | shares	0
Canceled and forfeited (in shares) | shares	0
Outstanding at end of period (in shares) | shares	8
Exercisable at end of period (in shares) | shares	5
Weighted-Average Exercise Price per Common Share
Outstanding at beginning of period (in usd per share) | $ / shares	$ 63.44
Granted (in usd per share) | $ / shares	66.44
Exercised (in usd per share) | $ / shares	0
Canceled and forfeited (in usd per share) | $ / shares	0
Outstanding at end of period (in usd per share) | $ / shares	64.30
Exercisable at end of period (in usd per share) | $ / shares	$ 59.19

Share-Based Compensation (Sch63

Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 35
Aggregate intrinsic value of outstanding options at period end	65		$ 109
Aggregate intrinsic value of exercisable options at period end	$ 65		$ 106
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years	7 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years	6 years

Share-Based Compensation (Sch64

Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units shares in Millions	3 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years
Restricted Share Units
Nonvested at beginning of period (in shares) | shares	2
Granted (in shares) | shares	1
Vested (in shares) | shares	(1)
Canceled and forfeited (in shares) | shares	0
Nonvested at end of period (in shares) | shares	2
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period (in usd per share) | $ / shares	$ 76.72
Granted (in usd per share) | $ / shares	66.44
Vested (in usd per share) | $ / shares	79.53
Canceled and forfeited (in usd per share) | $ / shares	0
Nonvested at end of period (in usd per share) | $ / shares	$ 71.60

Share-Based Compensation (Sch65

Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	133.00%
Performance Share Units
Nonvested at beginning of period (in shares) | shares	0.6
Granted (in shares) | shares	0.2
Vested (in shares) | shares	(0.2)
Canceled and forfeited (in shares) | shares	0
Nonvested at end of period (in shares) | shares	0.6
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period (in usd per share) | $ / shares	$ 77.83
Granted (in usd per share) | $ / shares	66.43
Vested (in usd per share) | $ / shares	71.57
Canceled and forfeited (in usd per share) | $ / shares	0
Nonvested at end of period (in usd per share) | $ / shares	$ 75.39
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $	$ 18
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years